LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $105.80 Consensus Price Target from Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been given a consensus rating of “Moderate Buy” by the seven research firms that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $105.80.

Several equities research analysts have recently weighed in on LMAT shares. Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Roth Mkm reiterated a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Barrington Research increased their target price on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Weiss Ratings upgraded shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, March 10th. Finally, Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st.

LeMaitre Vascular Price Performance

LMAT stock opened at $109.17 on Friday. The company has a market capitalization of $2.49 billion, a P/E ratio of 43.49, a PEG ratio of 3.08 and a beta of 0.66. The company has a fifty day moving average price of $97.78 and a 200-day moving average price of $90.30. The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.95 and a current ratio of 12.89. LeMaitre Vascular has a 52-week low of $71.42 and a 52-week high of $115.33.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.01. The company had revenue of $64.45 million for the quarter, compared to analysts’ expectations of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. LeMaitre Vascular’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, equities analysts expect that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 26th. Investors of record on Thursday, March 12th were paid a dividend of $0.25 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, March 12th. LeMaitre Vascular’s payout ratio is 39.84%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 150,000 shares of the stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $106.76, for a total transaction of $16,014,000.00. Following the completion of the sale, the chief executive officer directly owned 1,532,304 shares in the company, valued at approximately $163,588,775.04. This trade represents a 8.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David B. Roberts sold 8,464 shares of LeMaitre Vascular stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $106.80, for a total value of $903,955.20. Following the completion of the transaction, the director directly owned 17,979 shares of the company’s stock, valued at approximately $1,920,157.20. This trade represents a 32.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 215,438 shares of company stock worth $23,062,911 over the last quarter. Company insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada lifted its stake in LeMaitre Vascular by 1.5% in the first quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock valued at $9,579,000 after buying an additional 1,735 shares during the period. AQR Capital Management LLC grew its position in shares of LeMaitre Vascular by 36.4% during the 1st quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock worth $2,339,000 after buying an additional 7,445 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of LeMaitre Vascular by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock valued at $1,013,000 after acquiring an additional 539 shares in the last quarter. Millennium Management LLC increased its stake in shares of LeMaitre Vascular by 119.8% in the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after acquiring an additional 115,141 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of LeMaitre Vascular by 27.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after acquiring an additional 55,804 shares during the period. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.